RxDataLab Platform
Every clinical trial change, automatically detected.
ClinicalTrials.gov doesn't notify you when a trial changes. We monitor every registered biotech trial daily and surface what changed: endpoint modifications, enrollment shifts, arm updates, and stopped trials. Organized by company.
$499/mo
Cancel anytime. Access continues through the end of the billing period.
Detected this week
Recent trial changes caught automatically from ClinicalTrials.gov.
Updated Aug 30, 2026
The primary endpoints for mean and median calculated annualized bleed rate for treated bleeds had their timeframes extended from at least 52 weeks to a median of 156.07 weeks (up to 274 weeks). Additionally, several secondary endpoints related to annualized bleed rates were added, specifically focusing on 'Long-term Efficacy' with extended timeframes. The timeframes for many CATCH questionnaire and safety-related secondary endpoints were also extended, generally from approximately 48 months to approximately 274 weeks. Some secondary endpoints were removed, such as 'Change From Baseline in Body Temperature Over Time', 'Change From Baseline in Diastolic Blood Pressure Over Time', 'Change From Baseline in Pulse Rate Over Time', and 'Change From Baseline in Respiratory Rate Over Time'. New secondary endpoints were added, including 'Number of Participants With at Least One Adverse Events of Changes From Baseline in Vital Signs' and 'Number of Participants With at Least One Shifts in Clinical Laboratory Parameters From Baseline WHO Toxicity Scale Grade 0-2 to Post-baseline Grade 3 or 4'.
Status: ACTIVE_NOT_RECRUITING → COMPLETED
Number Of Arms: 11 → 13
Every item links to the original ClinicalTrials.gov record on the platform.
Trial monitoring
Trials can quietly change, don't miss it
Daily comparison against ClinicalTrials.gov. Every endpoint modification, enrollment shift, and status change categorized and summarized automatically.
NCT04158648
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors
Roche Holding Ltd RHHBY
Enrollment
73
Primary Completion
2021-10
Detected
Aug 28, 2026
Secondary endpoint 1 timeframe
Secondary endpoint 2 timeframe
+ 55 more endpoints modified
AI Summary
The primary endpoints for mean and median calculated annualized bleed rate for treated bleeds had their timeframes extended from at least 52 weeks to a median of 156.07 weeks (up to 274 weeks). Additionally, several secondary endpoints related to annualized bleed rates were added, specifically focusing on 'Long-term Efficacy' with extended timeframes. The timeframes for many CATCH questionnaire and safety-related secondary endpoints were also extended, generally from approximately 48 months to approximately 274 weeks. Some secondary endpoints were removed, such as 'Change From Baseline in Body Temperature Over Time', 'Change From Baseline in Diastolic Blood Pressure Over Time', 'Change From Baseline in Pulse Rate Over Time', and 'Change From Baseline in Respiratory Rate Over Time'. New secondary endpoints were added, including 'Number of Participants With at Least One Adverse Events of Changes From Baseline in Vital Signs' and 'Number of Participants With at Least One Shifts in Clinical Laboratory Parameters From Baseline WHO Toxicity Scale Grade 0-2 to Post-baseline Grade 3 or 4'.
Full change history per trial. Every detection timestamped and linked to the original registry record.
Subscribe to access →Change Detection
What gets caught.
ClinicalTrials.gov logs every update but doesn't surface them. We run a daily comparison and categorize every change.
Endpoint Modifications
Primary and secondary endpoint changes, new outcome measures added or removed, assessment timepoints shifted.
Enrollment Changes
Target enrollment updated, eligibility criteria modified, new sites added, age range or inclusion/exclusion criteria changed.
Status Shifts
Recruiting, suspended, terminated, completed. Caught the day the registry updates. Stopped trials flagged immediately.
Study Arms
Arms added or dropped, dosing changes, new intervention branches, comparator updates across multi-arm studies.
Company Pipeline View
Trials organized by company.
Every company mapped to their complete pipeline. Trials with recent changes flagged automatically. Sample from Solid Biosciences Inc. (SLDB).
Solid Biosciences Inc. SLDB
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT...
NCT07160634 · 80 enrolled
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
NCT06138639 · 60 enrolled
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
NCT07180355 · 10 enrolled
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (...
NCT07148089 · 18 enrolled
Pipeline View
Every company's full trial pipeline in one view
500+ biotech companies mapped to their complete clinical trial pipelines. Every Phase 1 through Phase 3 trial, linked to the company, not buried under NCT IDs. See exactly where each program is, what changed recently, and what's running in parallel.
Change History
Changes buried in ClinicalTrials.gov sponsor updates, surfaced automatically
Catch every endpoint modifications, enrollment count changes, or new arm added or dropped. Status changes from recruiting to suspended. We run a daily comparison against the registry and log every update, categorized, timestamped, and linked to the original record. Complete change history per trial.
app.rxdatalab.com
What's included.
Clinical trial tracking is one part of a broader platform built for BD, investors, and strategy teams who work from primary sources.
Monitor trial changes automatically
Daily comparison against ClinicalTrials.gov catches endpoint modifications, enrollment changes, arm updates, and status shifts. Don't miss a thing.
Track a company's complete pipeline
500+ biotech companies mapped to their trials. Every Phase 1 through NDA, organized by company rather than NCT ID. Every item links to the original registry record.
Hedge fund positioning in biotech
13D/G ownership disclosures: who's building positions, reducing stakes, or going activist. Cross-referenced with trial events and 8-Ks.
See live data sample →SEC filings classified by event type
8-K filings classified into financing events, FDA actions, clinical results, licensing deals, and strategic reviews. Search by company, date range, or type.
See live data sample →Map competitive landscapes by indication
Search any indication. Every industry trial mapped using NLM's MeSH ontology. Overlay recent trial events across the competitive field.
Projects and notes that stay with the data
Company and trial watchlists. Timestamped notes on trial and company pages. Dashboard shows what changed across your coverage since your last session.
Pricing
Simple, transparent pricing.
Individual — Monthly
Billed monthly. Cancel anytime from your account page.
- ✓ Full platform access
- ✓ BioHedge (13D/G fund positioning)
- ✓ Clinical trial change detection
- ✓ 8-K signal detection
- ✓ Competitive landscape mapping
- ✓ Research workspace and notes
Teams & Institutions
Custom pricing
For teams, firms, and institutional users who need multi-seat access, custom coverage, AI Access, API Access, or enterprise billing.
- ✓ Multi-seat access
- ✓ Custom data coverage and exports
- ✓ Invoiced billing and enterprise contracts
- ✓ API access and custom data feeds
- ✓ Dedicated support
What happens after payment?
You'll receive a welcome email with a link to set your password. Access immediately once your password is set.
How do I cancel?
Go to your account page and click "Manage Billing." Access continues through the end of your billing period.
Do you offer trials or demos?
The public pages at app.rxdatalab.com/biohedge and app.rxdatalab.com/strategic-signals show live data and require no login.
Questions or enterprise pricing?
Email [email protected] for team access, institutional pricing, or anything else.
By subscribing you agree to our Terms of Service and Data License Agreement.